How Analysts Feel About Teva Pharmaceutical Industries Limited (NYSE:TEVA)?

September 16, 2018 - By Matthew Richard

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Logo

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Coverage

Among 12 analysts covering Teva Pharma (NYSE:TEVA), 3 have Buy rating, 1 Sell and 8 Hold. Therefore 25% are positive. Teva Pharma had 16 analyst reports since March 20, 2018 according to SRatingsIntel. Citigroup maintained Teva Pharmaceutical Industries Limited (NYSE:TEVA) on Thursday, May 31 with “Buy” rating. Leerink Swann maintained it with “Sell” rating and $1600 target in Monday, June 11 report. The rating was maintained by Wells Fargo with “Sell” on Thursday, May 3. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Buy” rating given on Monday, May 7 by Mizuho. The firm has “Neutral” rating given on Monday, July 16 by Cantor Fitzgerald. Barclays Capital maintained the stock with “Equal-Weight” rating in Thursday, May 24 report. The stock has “Equal-Weight” rating by Barclays Capital on Monday, August 6. The company was maintained on Friday, August 3 by Morgan Stanley. Jefferies maintained the shares of TEVA in report on Tuesday, March 20 with “Hold” rating. The stock of Teva Pharmaceutical Industries Limited (NYSE:TEVA) has “Equal-Weight” rating given on Monday, May 7 by Morgan Stanley. Below is a list of Teva Pharmaceutical Industries Limited (NYSE:TEVA) latest ratings and price target changes.

07/09/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Neutral Old Target: $25 New Target: $23 Downgrade
06/08/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $20 New Target: $23 Maintain
03/08/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $19 New Target: $20 Maintain
16/07/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Neutral Old Target: $18 New Target: $25 Maintain
25/06/2018 Broker: Goldman Sachs Rating: Buy New Target: $28.0000 Upgrade
18/06/2018 Broker: Wells Fargo Old Rating: Underperform New Rating: Market Perform Upgrade
11/06/2018 Broker: Leerink Swann Rating: Sell New Target: $16.0000 Maintain
31/05/2018 Broker: Citigroup Old Rating: Buy New Rating: Buy Old Target: $24 New Target: $25 Maintain
24/05/2018 Broker: Guggenheim Rating: Hold Maintain
24/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $13 New Target: $20 Maintain

The stock increased 2.88% or $0.64 during the last trading session, reaching $22.85. About 11.57 million shares traded or 13.04% up from the average. Teva Pharmaceutical Industries Limited (NYSE:TEVA) has risen 14.85% since September 16, 2017 and is uptrending. It has underperformed by 0.77% the S&P500.

Teva Pharmaceutical Industries Limited develops, makes, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. The company has market cap of $23.27 billion. It operates through two divisions, Generic Medicines and Specialty Medicines. It currently has negative earnings. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

More notable recent Teva Pharmaceutical Industries Limited (NYSE:TEVA) news were published by: Nasdaq.com which released: “3 Top Large-Cap Stocks to Buy in September” on September 09, 2018, also Seekingalpha.com with their article: “Teva +5% as migraine treatment wins FDA approval” published on September 14, 2018, Seekingalpha.com published: “FDA OKs Teva’s opioid dependence med Cassipa” on September 07, 2018. More interesting news about Teva Pharmaceutical Industries Limited (NYSE:TEVA) were released by: Finance.Yahoo.com and their article: “Why Teva’s Outlook Is Mixed” published on August 23, 2018 as well as Seekingalpha.com‘s news article titled: “Key events next week – healthcare” with publication date: September 14, 2018.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.